Development of blood transfusion product pathogen reduction treatments: A review of methods, current applications and demands

Transfusion and Apheresis Science

Volumn 52, Issue 1, 2015, Pages 19-34

  Salunkhe, Vishal ^a   van der Meer, Pieter F ^b   de Korte, Dirk ^a,b   Seghatchian, Jerard ^c   Gutiérrez, Laura ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c International Consultancy in Blood Components Quality Safety Improvement   (United Kingdom)

Author keywords

Blood; Microvesicles; Pathogen inactivation; Pathogen reduction treatment; Plasma; Platelets; Red blood cells (RBC); Transfusion

Indexed keywords

AMOTOSALEN; METHYLENE BLUE; RIBOFLAVIN;

BLOOD BANK; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BLOODSTREAM INFECTION; DONOR SELECTION; HEAT TREATMENT; HUMAN; NANOFILTRATION; NONHUMAN; PATHOGEN CLEARANCE; PATHOGEN LOAD; PATHOGEN REDUCTION SYSTEM; PATHOGEN REDUCTION TREATMENT; PH; QUALITY CONTROL; REVIEW; SCREENING TEST; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRANSFUSION MEDICINE; TRANSFUSION TRANSMITTED INFECTION; VASCULARIZATION; ADVERSE EFFECTS; ANIMAL; BLOOD COMPONENT THERAPY; BLOODBORNE BACTERIUM; INSTRUMENT STERILIZATION; PROCEDURES; STANDARDS;

ANIMALS; BLOOD COMPONENT TRANSFUSION; BLOOD-BORNE PATHOGENS; HUMANS; STERILIZATION;

EID: 84926207959     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2014.12.016     Document Type: Review

References (126)

1. WHO. Blood safety and availability fact sheet. p. Fact Sheet Nr. 279; 2014.
2. American Cancer Society. Blood transfusion and donation; 2013.
3. Repine T.B., Perkins J.G., Kauvar D.S., Blackborne L. The use of fresh whole blood in massive transfusion. J Trauma 2006, 60:S59-S69.
4. Szczepiorkowski Z.M., Dunbar N.M. Transfusion guidelines: when to transfuse. Am Soc Hematol Educ Program 2013, 2013:638-644.
5. Allain J.P., Stramer S.L., Carneiro-Proietti A.B., Martins M.L., Lopes da Silva S.N., Ribeiro M., et al. Transfusion-transmitted infectious diseases. Biologicals 2009, 37:71-77.
6. de Korte D., Marcelis J.H. Platelet concentrates: reducing the risk of transfusion-transmitted bacterial infections. J Clin Transfus Med 2014, 2:29-37.
7. Allain J.P., Bianco C., Blajchman M.A., Brecher M.E., Busch M., Leiby D., et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005, 19:110-126.
8. Cable R.G., Leiby D.A. Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases. Curr Opin Hematol 2003, 10:405-411.
9. Theodossiades G., Makris M. Transfusion-transmitted infections: epidemiology, risks and prevention. Haema 2001, 4:24-38.
10. Brecher M.E., Hay S.N. Improving platelet safety: bacterial contamination of platelets. Curr Hematol Rep 2004, 3:121-127.
11. Goodrich R.P., Gilmour D., Hovenga N., Keil S.D. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009, 49:1205-1216.
12. Yomtovian R.A., Palavecino E.L., Dysktra A.H., Downes K.A., Morrissey A.M., Bajaksouzian S., et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 2006, 46:719-730.
13. Brecher M.E., Hay S.N. Bacterial contamination of blood components. Clin Microbiol Rev 2005, 18:195-204.
14. Kuehnert M.J., Roth V.R., Haley N.R., Gregory K.R., Elder K.V., Schreiber G.B., et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001, 41:1493-1499.
15. de Korte D., Curvers J., de Kort W.L., Hoekstra T., van der Poel C.L., Beckers E.A., et al. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006, 46:476-485.
16. AuBuchon J.P. Update on the status of pathogen inactivation methods. ISBT Sci Ser (Vox Sang) 2011, 6:181-188.
17. Custer B., Agapova M., Martinez R.H. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010, 50:2461-2473.
18. Epstein J.S., Vostal J.G. FDA approach to evaluation of pathogen reduction technology. Transfusion 2003, 43:1347-1350.
19. Seghatchian J., Putter J.S. Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion. Transfus Apher Sci 2013, 49:357-363.
20. Webert K.E., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008, 22:1-34.
21. Seghatchian J., Hervig T., Putter J.S. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates. Transfus Apher Sci 2011, 45:75-84.
22. Cardigan R., Williamson L.M. The quality of platelets after storage for 7 days. Transfus Med 2003, 13:173-187.
23. McClaskey J., Xu M., Snyder E.L., Tormey C.A. Clinical trials for pathogen reduction in transfusion medicine: a review. Transfus Apher Sci 2009, 41:217-225.
24. Stramer S.L., Hollinger F.B., Katz L.M., Kleinman S., Metzel P.S., Gregory K.R., et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009, 49(Suppl. 2):1S-29S.
25. Hess J.R. Red cell changes during storage. Transfus Apher Sci 2010, 43:51-59.
26. Bryant B.J., Klein H.G. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007, 131:719-733.
27. Seghatchian J., Allain J.P. Current strategies for the provision of safer plasma and its derivatives: an update. Transfus Apher Sci 2001, 25:185-187.
28. Jordan J., Tiangco B., Kiss J., Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998, 75:97-102.
29. Pamphilon D. Viral inactivation of fresh frozen plasma. Br J Haematol 2000, 109:680-693.
30. Solheim B.G., Rollag H., Svennevig J.L., Arafa O., Fosse E., Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion 2000, 40:84-90.
31. Hellstern P., Solheim B.G. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011, 38:65-70.
32. Octaplas.us. FDA Approves Octaplas® Expanding Octapharma U.S. Transfusion Medicine Therapies; 2013.
33. Heger A., Svae T.E., Neisser-Svae A., Jordan S., Behizad M., Romisch J. Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009, 97:219-225.
34. Solheim B.G. Pathogen reduction of blood components. Transfus Apher Sci 2008, 39:75-82.
35. Seghatchian J., de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006, 35:189-196.
36. Cardigan R., Philpot K., Cookson P., Luddington R. Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. Transfusion 2009, 49:696-703.
37. Dewachter P., Castro S., Nicaise-Roland P., Chollet-Martin S., Le Beller C., Lillo-le-Louet A., et al. Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 2011, 106:687-689.
38. Nubret K., Delhoume M., Orsel I., Laudy J.S., Sellami M., Nathan N. Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 2011, 51:125-128.
39. Pandey S., Vyas G.N. Adverse effects of plasma transfusion. Transfusion 2012, 52(Suppl. 1):65S-79S.
40. Larrea L., Calabuig M., Roldan V., Rivera J., Tsai H.M., Vicente V., et al. The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 2009, 41:199-204.
41. Irsch J., Pinkoski L., Corash L., Lin L. Intercept plasma: comparability with conventional fresh-frozen plasma based on coagulation function - an in vitro analysis. Vox Sang 2010, 98:47-55.
42. Burnouf T., Griffiths E., Padilla A., Seddik S., Stephano M.A., Gutierrez J.M. Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals 2004, 32:115-128.
43. Borkow G., Gabbay J. Copper as a biocidal tool. Curr Med Chem 2005, 12:2163-2175.
44. Borkow G., Lara H.H., Covington C.Y., Nyamathi A., Gabbay J. Deactivation of human immunodeficiency virus type 1 in medium by copper oxide-containing filters. Antimicrob Agents Chemother 2008, 52:518-525.
45. Borkow G., Sidwell R.W., Smee D.F., Barnard D.L., Morrey J.D., Lara-Villegas H.H., et al. Neutralizing viruses in suspensions by copper oxide-based filters. Antimicrob Agents Chemother 2007, 51:2605-2607.
46. AABB, American Association of Blood Banks . Listing of countries in which pathogen reduction technology systems and products are in use; 2013. http://AABB.org.
47. Svae T.E., Neisser-Svae A., Bailey A., Reichl H., Biesert L., Schmidt T., et al. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Transfus Apher Sci 2008, 39:59-67.
48. Macopharma. FAQ about Methylene Blue situation in France; 2014.
49. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014, 41:309-325.
50. Harmening D.M. Modern blood banking & transfusion practices 2012, 18-19. FAD Company. 6th ed.
51. Hanson C.V. Photochemical inactivation of viruses with psoralens: an overview. Blood Cells 1992, 18:7-25.
52. Lin L., Cook D.N., Wiesehahn G.P., Alfonso R., Behrman B., Cimino G.D., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997, 37:423-435.
53. Moroff G., Wagner S., Benade L., Dodd R.Y. Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethyltrimethylpsoralen and ultraviolet A light. Blood Cells 1992, 18:43-54. discussion 54-6.
54. van Rhenen D.J., Vermeij J., Mayaudon V., Hind C., Lin L., Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000, 79:206-214.
55. Osman A., Hitzler W.E., Meyer C.U., Landry P., Corduan A., Laffont B., et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2014, 1-10.
56. van Rhenen D., Gulliksson H., Cazenave J.P., Pamphilon D., Ljungman P., Kluter H., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
57. McCullough J., Vesole D.H., Benjamin R.J., Slichter S.J., Pineda A., Snyder E., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004, 104:1534-1541.
58. Janetzko K., Cazenave J.P., Kluter H., Kientz D., Michel M., Beris P., et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005, 45:1443-1452.
59. Kerkhoffs J.L., van Putten W.L., Novotny V.M., Te Boekhorst P.A., Schipperus M.R., Zwaginga J.J., et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010, 150:209-217.
60. Lozano M., Knutson F., Tardivel R., Cid J., Maymo R.M., Lof H., et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011, 153:393-401.
61. Marschner S., Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011, 38:8-18.
62. Ruane P.H., Edrich R., Gampp D., Keil S.D., Leonard R.L., Goodrich R.P. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004, 44:877-885.
63. Perez-Pujol S., Tonda R., Lozano M., Fuste B., Lopez-Vilchez I., Galan A.M., et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005, 45:911-919.
64. Li J., Goodrich L., Hansen E., Edrich R., Gampp D., Goodrich R.P. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage. Transfusion 2005, 45:1750-1758.
65. Zeddies S., De Cuyper I.M., van der Meer P.F., Daal B.B., de Korte D., Gutierrez L., et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014, 54:2292-2300.
66. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with Mirasol pathogen reduction technology. Transfusion 2010, 50:2362-2375. Mirasol Clinical Evaluation Study Group.
67. Asano H., Lee C.Y., Fox-Talbot K., Koh C.M., Erdinc M.M., Marschner S., et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007, 84:1174-1182.
68. Fast L.D., DiLeone G., Cardarelli G., Li J., Goodrich R. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Transfusion 2006, 46:1553-1560.
69. Seghatchian J., Tolksdorf F. Characteristics of the Theraflex UV-platelets pathogen inactivation system - an update. Transfus Apher Sci 2012, 46:221-229.
70. Seltsam A., Muller T.H. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011, 38:43-54.
71. Pohler P., Muller M., Winkler C., Schaudien D., Sewald K., Muller T.H., et al. Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products. Transfusion 2014.
72. Pohler P., Lehmann J., Veneruso V., Tomm J., von Bergen M., Lambrecht B., et al. Evaluation of the tolerability and immunogenicity of ultraviolet C-irradiated autologous platelets in a dog model. Transfusion 2012, 52:2414-2426.
73. Vamvakas E.C. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011, 51:1058-1071.
74. Vamvakas E.C. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012, 102:302-316.
75. Cid J., Escolar G., Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012, 103:322-330.
76. The Nederlands Trial Register. The PREPAReS Study: Pathogen Reduction Evaluation & Predictive Analytical Rating Score; 2014.
77. Bakkour S., Chafets D.M., Wen L., van der Meer P.F., Mundt J.M., Marschner S., et al. Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light. Vox Sang 2014, 107:351-359.
78. Macopharma. Theraflex UV-Platelets; 2014.
79. Benjamin R.J., McCullough J., Mintz P.D., Snyder E., Spotnitz W.D., Rizzo R.J., et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion 2005, 45:1739-1749.
80. Cancelas J.A., Dumont L.J., Rugg N., Szczepiorkowski Z.M., Herschel L., Siegel A., et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011, 51:2367-2376.
81. Information on Clinical Trials and Human Research Studies (). Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs) in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion; 2014. http://ClinicalTrials.gov.
82. Cancelas J.A., Rugg N., Fletcher D., Pratt P.G., Worsham D.N., Dunn S.K., et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011, 51:1460-1468.
83. Goodrich R.P., Doane S., Reddy H.L. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010, 38:20-30.
84. Reddy H.L., Doane S.K., Keil S.D., Marschner S., Goodrich R.P. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013, 53(Suppl. 1):131S-136S.
85. Goodrich R.P., Murthy K.K., Doane S.K., Fitzpatrick C.N., Morrow L.S., Arndt P.A., et al. Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons. Transfusion 2009, 49:64-74.
86. Roberts P.L., Dalton J., Evans D., Harrison P., Li Z., Ternouth K., et al. Removal of TSE agent from plasma products manufactured in the United Kingdom. Vox Sang 2013, 104:299-308.
87. Mays C.E., Joy S., Li L., Yu L., Genovesi S., West F.G., et al. Prion inhibition with multivalent PrPSc binding compounds. Biomaterials 2012, 33:6808-6822.
88. Korth C., May B.C., Cohen F.E., Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001, 98:9836-9841.
89. Ghaemmaghami S., Ahn M., Lessard P., Giles K., Legname G., DeArmond S.J., et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 2009, 5:e1000673.
90. Bian J., Kang H.E., Telling G.C. Quinacrine promotes replication and conformational mutation of chronic wasting disease prions. Proc Natl Acad Sci U S A 2014, 111:6028-6033.
91. Yamasaki T., Suzuki A., Hasebe R., Horiuchi M. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells. PLoS ONE 2014, 9:e106516.
92. Murphy C.V., Eakins E., Fagan J., Croxon H., Murphy W.G. In vitro assessment of red-cell concentrates in SAG-M filtered through the MacoPharma P-CAPT prion-reduction filter. Transfus Med 2009, 19:109-116.
93. Sowemimo-Coker S., Kascsak R., Kim A., Andrade F., Pesci S., Kascsak R., et al. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter. Transfusion 2005, 45:1839-1844.
94. Heger A., Bailey A., Neisser-Svae A., Ertl M., Romisch J., Svae T.E. Removal of prion infectivity by affinity ligand chromatography during OctaplasLG(R) manufacturing - results from animal bioassay studies. Vox Sang 2012, 102:294-301.
95. Sanquin. Plasma products: Omniplasma; 2014.
96. WHO. Background document: potential Ebola therapies and vaccines; 2014.
97. WHO. Position paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response; 2014.
98. Gulland A. First Ebola treatment is approved by WHO. BMJ 2014, 349:g5539.
99. Burnouf T., Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci 2014, 51:120-125.
100. Schubert P., Devine D.V. Proteomics meets blood banking: identification of protein targets for the improvement of platelet quality. J Proteomics 2010, 73:436-444.
101. Shevchenko A., Tomas H., Havlis J., Olsen J.V., Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 2006, 1:2856-2860.
102. Thiele T., Steil L., Volker U., Greinacher A. Proteomics of blood-based therapeutics: a promising tool for quality assurance in transfusion medicine. Biodrugs 2007, 21:179-193.
103. Schubert P., Culibrk B., Coupland D., Scammell K., Gyongyossy-Issa M., Devine D.V. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012, 52:397-408.
104. Marrocco C., D'Alessandro A., Girelli G., Zolla L. Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. Transfusion 2013, 53:1808-1820.
105. Thiele T., Sablewski A., Iuga C., Bakchoul T., Bente A., Gorg S., et al. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation - a LC-ESI-MS/MS-based proteomics approach. Blood Transfus 2012, 10(Suppl. 2):s63-s70.
106. Hechler B., Ohlmann P., Chafey P., Ravanat C., Eckly A., Maurer E., et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013, 53:1187-1200.
107. Mohr H., Steil L., Gravemann U., Thiele T., Hammer E., Greinacher A., et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009, 49:2612-2624.
108. Prudent M., Sonego G., Abonnenc M., Tissot J.D., Lion N. LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets. J Am Soc Mass Spectrom 2014, 25:651-661.
109. Krailadsiri P., Seghatchian J., Bode A.P. Microvesicles in blood components: laboratory and clinical aspects. Clin Appl Thromb Hemost 1997, 3:86-95.
110. Lemoinne S., Thabut D., Housset C., Moreau R., Valla D., Boulanger C.M., et al. The emerging roles of microvesicles in liver diseases. Nat Rev Gastroenterol Hepatol 2014, 11:350-361.
111. Krailadsiri P., Seghatchian J., Macgregor I., Drummond O., Perrin R., Spring F., et al. The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components. Transfusion 2006, 46:407-417.
112. Gitz E., Pollitt A.Y., Gitz-Francois J.J., Alshehri O., Mori J., Montague S., et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 2014, 124:2262-2270.
113. Tissot J.-D., Canellini G., Rubin O., Angelillo-Scherrer A., Delobel J., Prudent M., et al. Blood microvesicles: from proteomics to physiology. Transl Proteomics 2013, 1:38-52.
114. van der Pol E., Coumans F., Varga Z., Krumrey M., Nieuwland R. Innovation in detection of microparticles and exosomes. J Thromb Haemost 2013, 11(Suppl. 1):36-45.
115. Aatonen M.T., Ohman T., Nyman T.A., Laitinen S., Gronholm M., Siljander P.R. Isolation and characterization of platelet-derived extracellular vesicles. J Extracell Vesicles 2014, 3.
116. Nollet K.E., Saito S., Ono T., Ngoma A., Ohto H. Microparticle formation in apheresis platelets is not affected by three leukoreduction filters. Transfusion 2013, 53:2293-2298.
117. Garcia B.A., Smalley D.M., Cho H., Shabanowitz J., Ley K., Hunt D.F. The platelet microparticle proteome. J Proteome Res 2005, 4:1516-1521.
118. Varon D., Hayon Y., Dashevsky O., Shai E. Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration. Thromb Res 2012, 130(Suppl. 1):S98-S99.
119. Varon D., Shai E. Role of platelet-derived microparticles in angiogenesis and tumor progression. Discov Med 2009, 8:237-241.
120. Bosman G.J., Lasonder E., Groenen-Dopp Y.A., Willekens F.L., Werre J.M. The proteome of erythrocyte-derived microparticles from plasma: new clues for erythrocyte aging and vesiculation. J Proteomics 2012, 76:203-210. Spec No.
121. Kriebardis A.G., Antonelou M.H., Stamoulis K.E., Economou-Petersen E., Margaritis L.H., Papassideri I.S. RBC-derived vesicles during storage: ultrastructure, protein composition, oxidation, and signaling components. Transfusion 2008, 48:1943-1953.
122. Almizraq R., Tchir J.D., Holovati J.L., Acker J.P. Storage of red blood cells affects membrane composition, microvesiculation, and in vitro quality. Transfusion 2013, 53:2258-2267.
123. Rubin O., Delobel J., Prudent M., Lion N., Kohl K., Tucker E.I., et al. Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion 2013, 53:1744-1754.
124. Boudreau L.H., Duchez A.C., Cloutier N., Soulet D., Martin N., Bollinger J., et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood 2014, 124:2173-2183.
125. Borkow G., Doucoure A. Neutralising pathogens in blood in developing countries - thinking outside the screening box. Eur Hematol 2008, 2:85-88.
126. Solheim B.G., Seghatchian J. Rossi's principles of transfusion medicine 2009, W-BP Ltd. 4th ed.